BCM
IMUX icon

Bluefin Capital Management’s Immunic IMUX Stock Holding History

Bluefin Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-39
Closed -$63K – 729
2015
Q3 		$63K Buy
+39
New +$195K ﹤0.01% 399

Other funds holding IMUX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bluefin Capital Management's IMUX Position: Q4 2015 in Review

Bluefin Capital Management sold out of Immunic (IMUX) in Q4 2015, closing a stake of 39 shares — an estimated $63K sold.

Bluefin Capital Management first reported a position in IMUX in Q3 2015 and held it in 1 quarter. The position peaked at $63K in Q3 2015. 54 funds tracked by Wall St. Rank hold IMUX as of Q4 2015.

  • Bluefin Capital Management reported no remaining Immunic position as of Q4 2015 after selling out during the quarter.
  • Bluefin Capital Management sold 39 Immunic shares in Q4 2015, an estimated $63K.
  • Bluefin Capital Management first reported a position in Immunic in Q3 2015 and held it in 1 quarter.
  • Bluefin Capital Management's Immunic position peaked at $63K in Q3 2015.
  • 54 funds tracked by Wall St. Rank held Immunic as of Q4 2015.

Based on Bluefin Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.